<DOC>
	<DOCNO>NCT02370758</DOCNO>
	<brief_summary>This study evaluate whether test Cytomegalovirus ( CMV ) specific cell-mediated immunity use determine whether patient complete course therapy CMV viremia need secondary antiviral prophylaxis . Subjects negative CMV CMI receive antiviral prophylaxis 2 month positive CMV CMI prophylaxis stop .</brief_summary>
	<brief_title>Cell Mediated Immunity Secondary Prophylaxis CMV SOT Patients</brief_title>
	<detailed_description>Cytomegalovirus ( CMV ) important infection transplant patient common cause illness patient undergone transplant . Serious infection due CMV affect many part body include lung , gut , liver ; CMV infection become serious enough cause symptom , call CMV disease . Some patient require treatment others clear virus . QuantiFERON-CMV ( QFT-CMV ) blood test measure CMV-specific cell-mediated immunity . This test able predict patient low cell-mediated immunity great risk develop CMV disease . In study , QFT-CMV use make decision regard CMV treatment . The QFT-CMV test perform first detection CMV , end antiviral therapy one month post-therapy . The end-of-therapy result available clinician study investigator within one week collection . Based result , decision make continue prolonged antiviral therapy . Patients show weak cell-mediated immunity CMV give secondary antiviral prophylaxis , patient good cell-mediated immunity therapy stop . Patients continue monitor three month last QFT-CMV test recurrent CMV viremia . This study also attempt evaluate predictive value QuantiFERON-Monitor ( QFT-Monitor ) assay . QFT-Monitor recently develop non-pathogen specific immune assay : base immune activation innate adaptive immunity . The investigator hypothesize stimulation innate adaptive immunity may predict global immune function also predictive CMV reactivation . The investigator plan perform QFT-Monitor assay parallel QFT-CMV test determine test characteristic cut-off value predict global immune function . This test collect tested batch . Therefore , result influence clinical decision .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Adult solid organ transplant ( SOT ) recipient least one immunosuppressive medication Starting therapy new onset asymptomatic CMV viremia OR start therapy new onset CMV disease CMV viral load â‰¥ 1000 IU/mL Known ganciclovirresistant CMV Known intolerance valganciclovir ganciclovir Unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Quantiferon-CMV</keyword>
	<keyword>Quantiferon-Monitor</keyword>
	<keyword>Solid Organ Transplants</keyword>
	<keyword>CMV Disease</keyword>
</DOC>